MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on October 6, 2006; DOI: 10.1124/mol.106.025015


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.025015v1
71/1/83    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lima, W.
Right arrow Articles by Crooke, S. T
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lima, W.
Right arrow Articles by Crooke, S. T


Received for publication April 11, 2006.
Revised October 4, 2006.
Accepted for publication October 4, 2006.

Human RNase H1 discriminates between subtle variations in the structure of the heteroduplex substrate

Walt Lima 1*, John B Rose 1, Josh G Nichols 1, Hongjiang Wu 1, Michael T Migawa 1, Tadeusz K Wyrzykiewicz 1, Andrew M Siwkowski 2, Stanley T Crooke 1

1 Isis Pharmaceuticals Inc. 2 Isis Pharmaceuticals

* Address correspondence to: E-mail: wlima{at}isisph.com

Abstract

In a previous study we demonstrated that the sugar conformation and helical geometry of the heteroduplex substrate at the catalytic site of human RNase H1 directs the selective recognition of the substrate by the enzyme (Lima, W. F., Nichols, J. G., Wu, H-J., Prakash, T. P., Migawa, M. T., Wyrzykiewicz, T. K., Bhat, B., Crooke, S. T. (2004) J. Biol. Chem. 279, 36317-36326). Here, we systematically introduced 2'-methoxyethoxy (MOE) nucleotides into the antisense oligodeoxyribonucleotide (ASO) of the heteroduplex to alter the helical geometry of the substrate. The MOE substitutions at the 3' and 5'-poles of the ASO resulted in fewer cleavage sites and slower cleavage rates compared to the unmodified substrates. Further, a greater reduction in cleavage activity was observed for MOE substitutions at the 5'-pole of the ASO. The 3'-most and 5'-most cleavage sites were positioned, respectively, 2 and 4-5 base-pairs from the nearest MOE residues suggesting a conformational transmission of the MOE/RNA helical geometry into the DNA/RNA portion of the heteroduplex. Similar conformational transmission was observed for Okazaki-like substrates containing deoxyribonucleotide substitutions at the 3'-pole of the oligoribonucleotide. Finally, the heteroduplex substrates exhibited preferred cleavage sites, which were cleaved 2 to 3-fold faster than other sites in the substrate and these sites exhibited the greatest influence on the initial cleavage rates. The data presented here offer further insights into the role substrate structure plays in directing human RNase H1 activity as well as the design of effective ASOs.


Key words: Enzymology, Regulation - post-transcriptional, Antisense


This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
S. I. Rudnick, J. Swaminathan, M. Sumaroka, S. Liebhaber, and A. M. Gewirtz
Effects of local mRNA structure on posttranscriptional gene silencing
PNAS, September 16, 2008; 105(37): 13787 - 13792.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
W. F. Lima, J. B. Rose, J. G. Nichols, H. Wu, M. T. Migawa, T. K. Wyrzykiewicz, G. Vasquez, E. E. Swayze, and S. T. Crooke
The Positional Influence of the Helical Geometry of the Heteroduplex Substrate on Human RNase H1 Catalysis
Mol. Pharmacol., January 1, 2007; 71(1): 73 - 82.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics